Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase.

Xu HT, Colby-Germinario SP, Hassounah S, Quashie PK, Han Y, Oliveira M, Stranix BR, Wainberg MA.

Antimicrob Agents Chemother. 2015 Nov 16;60(1):600-8. doi: 10.1128/AAC.02203-15.

2.

Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.

Hassounah SA, Liu Y, Quashie PK, Oliveira M, Moisi D, Brenner BG, Sandstrom PA, Mesplède T, Wainberg MA.

J Virol. 2015 Dec;89(23):12002-13. doi: 10.1128/JVI.02131-15. Epub 2015 Sep 16.

PMID:
26378179
3.

The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B.

Mesplède T, Quashie PK, Hassounah S, Osman N, Han Y, Liang J, Singhroy DN, Wainberg MA.

AIDS. 2015 Jul 31;29(12):1459-66. doi: 10.1097/QAD.0000000000000752.

PMID:
26244385
4.

Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout.

Osman N, Mesplède T, Quashie PK, Oliveira M, Zanichelli V, Wainberg MA.

J Antimicrob Chemother. 2015 Oct;70(10):2810-5. doi: 10.1093/jac/dkv176. Epub 2015 Jul 4.

PMID:
26142476
5.

Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor.

Quashie PK, Han YS, Hassounah S, Mesplède T, Wainberg MA.

PLoS One. 2015 Jun 5;10(6):e0128310. doi: 10.1371/journal.pone.0128310. eCollection 2015.

6.

A resveratrol analog termed 3,3',4,4',5,5'-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor.

Han YS, Quashie PK, Mesplède T, Xu H, Quan Y, Jaeger W, Szekeres T, Wainberg MA.

J Med Virol. 2015 Dec;87(12):2054-60. doi: 10.1002/jmv.24271. Epub 2015 Jun 9.

PMID:
25989218
7.

Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.

Xu HT, Colby-Germinario SP, Quashie PK, Bethell R, Wainberg MA.

Antimicrob Agents Chemother. 2015;59(6):3189-96. doi: 10.1128/AAC.00315-15. Epub 2015 Mar 16.

8.

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.

Quashie PK, Oliviera M, Veres T, Osman N, Han YS, Hassounah S, Lie Y, Huang W, Mesplède T, Wainberg MA.

J Virol. 2015 Mar;89(6):3163-75. doi: 10.1128/JVI.03353-14. Epub 2014 Dec 31.

9.

HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase.

Depatureaux A, Quashie PK, Mesplède T, Han Y, Koubi H, Plantier JC, Oliveira M, Moisi D, Brenner B, Wainberg MA.

Antimicrob Agents Chemother. 2014 Dec;58(12):7141-50. doi: 10.1128/AAC.03819-14. Epub 2014 Sep 15.

10.

Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.

Hassounah SA, Mesplède T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA.

J Virol. 2014 Sep 1;88(17):9683-92. doi: 10.1128/JVI.00947-14. Epub 2014 Jun 11.

11.

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.

Mesplède T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA.

J Antimicrob Chemother. 2014 Oct;69(10):2733-40. doi: 10.1093/jac/dku199. Epub 2014 Jun 10.

12.

Integrase strand transfer inhibitors in the management of HIV-positive individuals.

Mesplède T, Quashie PK, Zanichelli V, Wainberg MA.

Ann Med. 2014 May;46(3):123-9. doi: 10.3109/07853890.2014.883169. Epub 2014 Mar 3. Review.

PMID:
24579911
13.

Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors.

Oliveira M, Mesplède T, Quashie PK, Moïsi D, Wainberg MA.

AIDS. 2014 Mar 27;28(6):813-9. doi: 10.1097/QAD.0000000000000199.

PMID:
24463394
14.

The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.

Wares M, Mesplède T, Quashie PK, Osman N, Han Y, Wainberg MA.

Retrovirology. 2014 Jan 17;11:7. doi: 10.1186/1742-4690-11-7.

15.

Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.

Quashie PK, Mesplède T, Han YS, Veres T, Osman N, Hassounah S, Sloan RD, Xu HT, Wainberg MA.

Antimicrob Agents Chemother. 2013 Dec;57(12):6223-35. doi: 10.1128/AAC.01835-13. Epub 2013 Sep 30. Erratum in: Antimicrob Agents Chemother. 2014 Jan;58(1):633.

16.

Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity.

Singhroy DN, Mesplède T, Sabbah A, Quashie PK, Falgueyret JP, Wainberg MA.

Retrovirology. 2013 Jul 17;10:73. doi: 10.1186/1742-4690-10-73.

17.

Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors.

Han YS, Xiao WL, Quashie PK, Mesplède T, Xu H, Deprez E, Delelis O, Pu JX, Sun HD, Wainberg MA.

Antiviral Res. 2013 Jun;98(3):441-8. doi: 10.1016/j.antiviral.2013.04.001. Epub 2013 Apr 9.

PMID:
23583286
18.

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure.

Mesplède T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA.

Retrovirology. 2013 Feb 22;10:22. doi: 10.1186/1742-4690-10-22.

19.

Evolution of HIV integrase resistance mutations.

Quashie PK, Mesplède T, Wainberg MA.

Curr Opin Infect Dis. 2013 Feb;26(1):43-9. doi: 10.1097/QCO.0b013e32835ba81c. Review. Erratum in: Curr Opin Infect Dis. 2014 Jun;27(3):302. Curr Opin Infect Dis. 2014 Aug;27(4):401.

PMID:
23242340
20.

HIV Drug Resistance and the Advent of Integrase Inhibitors.

Quashie PK, Mesplède T, Wainberg MA.

Curr Infect Dis Rep. 2013 Feb;15(1):85-100. doi: 10.1007/s11908-012-0305-1.

PMID:
23180144
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk